Compare Immunovant Inc. Common Stock (IMVT) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Sherwin-Williams Company (The) Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $27.97 (market cap $5.93B), while Sherwin-Williams Company (The) Common Stock trades at $327.33 (market cap $78.68B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 13.3× Immunovant Inc. Common Stock's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IMVT | SHW | |
|---|---|---|
Market Cap | $5.93B | $78.68B |
Volume | 1,242,632 | 1,245,324 |
Sector | Health | Basic Materials |
52-Week High | $44.96 | $372.60 |
52-Week Low | $17.41 | $293.00 |
Typical Hold Time | 6 Days | — |
Enterprise Value | $5.03B | $92.60B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Immunovant (IMVT) trades at $28.71, down 2.61% with bearish technical signals despite strong analyst support. The company shows no revenue with substantial losses (-$413.84M net income) and negative margins, though it maintains a robust cash position from recent financing. Recent clinical setbacks, including the discontinuation of IMVT-1402 for cutaneous lupus, have pressured the stock, while multiple law firm investigations into potential fiduciary breaches add uncertainty.
The investment case hinges on IMVT-1402's success in other indications like Graves' disease, with a bullish analyst consensus (78% buy ratings) contrasting high execution risks. Key risks include clinical trial outcomes, cash burn, and legal overhangs. The stock's viability depends heavily on pipeline progress against a backdrop of persistent losses and volatile sentiment.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
